Keyphrases
Japanese Patients
100%
Old Japanese
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Type 2 Diabetic Patients
100%
Empagliflozin
100%
Systolic Blood Pressure
50%
Nocturnal Hypertension
50%
Elderly Diabetes
33%
Cardiovascular Risk
16%
High Risk
16%
No Significant Difference
16%
Placebo
16%
Safety Outcomes
16%
Elderly Patients
16%
Heart Failure
16%
Combination Therapy
16%
Efficacy Outcomes
16%
Patients with Diabetes
16%
Hypotension
16%
Age Groups
16%
Nighttime
16%
Angiotensin Receptor Blockers
16%
Glycated Hemoglobin
16%
Uric Acid
16%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
16%
Hypoglycemic Episodes
16%
Age Group Differences
16%
Event Failure
16%
T2DM Patients
16%
Metabolic Adverse Events
16%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Post-Hoc Analysis
100%
Patient with Type 2 Diabetes
100%
Empagliflozin
100%
Systolic Blood Pressure
50%
Diabetes Mellitus
33%
Type 2 Diabetes
33%
Body Weight
16%
Adverse Event
16%
Hypotension
16%
Cardiovascular System
16%
Combination Therapy
16%
Elderly Patient
16%
Heart Failure
16%
Placebo
16%
Patient with Diabetes
16%
Angiotensin Receptor Antagonist
16%
Antidiabetic Agent
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%
Glycated Hemoglobin
16%
Uric Acid
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Empagliflozin
100%
Diabetes Mellitus
33%
Adverse Event
16%
Hypotension
16%
Combination Therapy
16%
Placebo
16%
Heart Failure
16%
Glycosylated Hemoglobin
16%
Depressed Blood Pressure
16%
Antidiabetic Agent
16%
Uric Acid
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%
Angiotensin Receptor Antagonist
16%